Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Filip Y. F. de Vos
Utrecht University - Department of Medical Oncology
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
26
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Health-Related Quality of Life Results from the Randomized Phase Ii Tavarec Trial on Temozolomide With or Without Bevacizumab in 1p/19q Intact First Recurrence Who Grade 2 and 3 Glioma (Eortc 26091)
Number of pages: 19
Posted: 12 May 2023
Jaap C. Reijneveld
,
Abigirl Machingura
,
Corneel Coens
,
Martin J. B. Taphoorn
,
Walter Taal
,
Paul M. Clement
,
Ahmed Idbaih
, Filip Y. F. de Vos,
Martin Klein
,
Wolfgang Wick
,
Paul J. Mulholland
,
Joanne Lewis
,
Vassilis Golfinopoulos
,
Irina Ghislain
,
Andrew Bottomley
,
Martin van den Bent
and
EORTC Brain Tumor Group
University of Amsterdam - Amsterdam University Medical Centers, European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for Research and Treatment of Cancer (EORTC), Leiden University, Erasmus University Rotterdam (EUR) - Erasmus Medical Center (MC), KU Leuven, Sorbonne University, Utrecht University - Department of Medical Oncology, University of Amsterdam - Amsterdam University Medical Centers, Heidelberg University - University Hospital Heidelberg, University College Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for Research and Treatment of Cancer (EORTC), Erasmus MC - Brain Tumor Centre and Independent
Downloads
26
(1,372,601)
View PDF
Download
Abstract:
Health-related quality of life, glioma, bevacizumab, temozolomide, EORTC, RCTs
Feedback